Development of byom-1119 for the prevention and treatment of pancreatic cancer metastases and cachexia

Byomass Inc. received a $694,935 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective November 1, 2025, through October 31, 2027. The award supports the development of BYOM-1119, a novel therapeutic candidate designed for the prevention and treatment of pancreatic cancer metastases and cachexia. The research and development activities will be conducted at the company's facility in Sudbury, Massachusetts.

This award represents continued investment in Byomass Inc.'s oncology research portfolio, building upon the company's established expertise in antibody development and cancer-related therapeutics. The Military Medical Research and Development program supports hypothesis-driven biomedical research initiatives designed to address critical health challenges for both military service members and the broader American public through innovative medical solutions. The two-year performance period aligns with the program's typical funding structure, which supports diverse research domains including oncology, immunotherapy, and therapeutic development at eligible research institutions nationwide.